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Available online at www.sciencedirect.comGlaucoma is a progressive optic neuropathy of unknown origin.
It has been hypothesized that a vascular component is involved
in glaucoma pathophysiology. This hypothesis has gained
support from studies showing that reduced ocular perfusion
pressure is a risk factor for the disease. The exact nature of the
involvement is, however, still a matter of debate. Based on
recent evidence we propose a model including primary and
secondary insults in glaucoma. The primary insult appears to
happen at the optic nerve head. Increased intraocular pressure
and ischemia at the post-laminar optic nerve head affects
retinal ganglion cell axons. Modulating factors are the
biomechanical properties of the tissues and cerebrospinal fluid
pressure. After this primary insult retinal ganglion cells function
at a reduced energy level and are sensitive to secondary
insults. These secondary insults may happen if ocular perfusion
pressure falls below the lower limit of autoregulation or if
neurovascular coupling fails. Evidence for both faulty
autoregulation and reduced hyperemic response to neuronal
stimulation has been provided in glaucoma patients. The
mechanisms appear to involve vascular endothelial
dysfunction and impaired astrocyte-vessel signaling. A more
detailed understanding of these pathways is required to direct
neuroprotective strategies via the neurovascular pathway.
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Introduction
Glaucoma is a family of multifactorial optical neuropa-
thies characterized by loss of retinal ganglion cells
(RGCs) leading to typical optic nerve head (ONH)
damage and distinctive visual field defects. Although
the pathogenesis of the disease is unknown, it is well
established that the main risk factor for glaucoma is
Open access under CC BY-NC-ND license.Current Opinion in Pharmacology 2013, 13:36–42 elevated intraocular pressure (IOP). Reducing IOP is
effective in slowing down the progression of the disease
but some patients still progress despite adequately con-
trolled IOP.
Several studies implicated vascular risk factors in the
pathogenesis of glaucoma, blood pressure (BP) and
ocular perfusion pressure (OPP) being the most studied.
This vascular hypothesis is based on the premise that
abnormal perfusion and the subsequent ischemia of the
ONH play a major role in the glaucomatous damage.
The OPP is the difference between arterial and venous
BP. In the eye the venous pressure almost equals IOP.
As such the OPP can be estimated as the difference
between the arterial pressure and IOP. The relationship
between BP and glaucoma is complex and controversial.
On the one hand some studies indicate that systemic
hypertension is a risk factor for glaucoma [1–3]. On the
other hand some studies indicate that low systemic BP is
a risk factor for development and progression of glau-
coma. A direct and clear relationship between BP level
and glaucomatous damage has, however, not been estab-
lished [4]. The good irrigation of the ocular tissues is
ensured by an adequate OPP depending on a complex
regulation process that balances BP and the IOP. As
such dealing with the concept of OPP and BP at the
same time is more pertinent.
Large epidemiological studies have shown that low OPP
is a risk factor for the prevalence, incidence and pro-
gression of glaucoma. In the Barbados Eye Study [5] low
systolic BP doubled the risk for glaucoma incidence.
Subjects with the lowest 20% of diastolic perfusion pres-
sure were 3.3 times more likely to develop glaucoma. In
the Proyecto VER Study [6] it was established that
patients with a diastolic perfusion pressure as low as
45 mmHg had a three times greater risk of developing
glaucoma compared to those with a diastolic perfusion
pressure of 65 mmHg. This is in keeping with data from
the Egna–Neumarkt Study [1] showing that the preva-
lence of the disease in patients with diastolic perfusion
pressure less than 50 mmHg increases 4.5 fold compared
to patients with diastolic perfusion pressure of 65 mmHg.
Data on glaucoma progression are available from The
Early Manifest Glaucoma Trial (EMGT). Patients with
low systolic perfusion pressure at baseline progressed
faster than their counterparts. Low systolic perfusion
pressure was a predictor of progression with an almost
50% higher risk [7]. More in depth reviews on the datawww.sciencedirect.com
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progression have been provided [4,8,9]. This review,
however, will formulate some hypotheses as to why
OPP is a risk factor.
Why is low OPP a risk factor for glaucoma?
Vascular factors have been identified in many chronic
neurodegenerative disorders including Alzheimer’s dis-
ease and amyotrophic lateral sclerosis [10]. In glaucoma
the hypothesis of a vascular involvement in the disease
process has been formulated a long time ago. The evi-
dence that low OPP is a risk factor for the disease has
further supported this concept. Calculation of OPP as
presented above is only an estimate of the true OPP.
Indeed it assumes that mean arterial pressure (MAP) as
measured at the brachial artery is a good measure of MAP
at the level of the ophthalmic artery. To which degree this
assumption is fulfilled, however, is not clear. In addition,Figure 1
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IOP is always slightly lower than pressure in retinal or
choroidal veins [11,12]. In addition, there is evidence that
the difference between venous pressure and IOP is
increased in patients with glaucoma. This is related to
the phenomenon of spontaneous venous pulsations in the
central retinal vein, which appear to be a risk factor for
glaucoma [13]. Hence our current way of estimating OPP
involves both systematic and statistical errors. As such it is
likely that the relationship between true OPP and glau-
comatous damage is much stronger than indicated above.
Whilst it is well-established that reduced OPP (as cur-
rently estimated) is a risk factor for glaucoma there is
considerable controversy as to why this is the case. In the
following we present a theory describing pathways that
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38 Neurosciencesof RGCs is the consequence of primary and secondary
insults as suggested previously [14]. The site of primary
insult to RGC axons in glaucoma is most likely within the
ONH, more specifically at the lamina cribrosa. Increased
IOP may be responsible for this loss of RGC axons
modulated by the biomechanical properties of the ocular
tissues [15,16,17] and the level of cerebrospinal fluid
pressure (CSF) [18–20]. As such, low CSF pressure may
be one of the factors by which OPP modulates the risk of
glaucoma because changes in either of them lead to a
change in the trans-lamina cribrosa pressure gradient.
Another factor in the primary glaucomatous insult that
may be enhanced by low OPP is ONH ischemia associ-
ated with reduced flow of nutrients to the RGC axons.
Some investigators assume that this ischemia at the ONH
is primary and at least in some cases associated with
systemic disease [21]. Another possibility is that IOP-
related strain within the peri-papillary sclera affects per-
fusion through the scleral branches of the short posterior
ciliary arteries [17]. The vasculature of the ONH is
complex and the post-laminar regions of the ONH are
supplied by branches of the posterior ciliary arteries [22].
Owing to its deep anatomical location little is known
about blood flow (BF) and its regulation in this part of the
ONH. Most quantitative data about ONH BF regulation
stem from the anterior ONH regions that are supplied by
the central retinal artery [23].
Once a primary insult has occurred at the level of the
ONH RGCs appear to function at reduced energy levels
with affected mitochondria. This is supported by numer-
ous experimental data [14,24] including electrophysio-
logical studies in the primate revealing that affected
RGCs retain some of their functionality [25]. As such
neuroprotective strategies may be implemented to rescue
injured RGCs independently of the primary insult.
Indeed targeting mitochondria may offer a wide range
of strategies for RGC survival including the dynamic
processes of mitochondrial fission and fusion, the electron
transport chain components, ion channels and defense
strategies against oxidative stress.
Oxidative stress associated with extensive production of
reactive oxygen species (ROS) such as free radicals,
hydrogen peroxide, or singlet oxygen is another factor
that may be enhanced by ischemia associated with low
OPP. Free radicals are molecules containing unpaired
electrons in their outer orbits. Singlet oxygen and hydro-
gen peroxide do not have unpaired electrons but are
unstable and in a reactive state. ROS are constantly
produced in cells. Oxidative stress occurs when the
balance between production of ROS and endogenous
antioxidative defense systems is disturbed either owing
to increased ROS activity or owing to reduced antiox-
idative capacity. Ischemia and ischemia/reperfusion are
classic triggers for ROS generation and oxidative stress.Current Opinion in Pharmacology 2013, 13:36–42 Oxidative stress offers a potential target for neuroprotec-
tion in glaucoma. Strategies may be wide and include
inhibition of ROS formation, administration and/or
supplementation with antioxidants or with agents that
increase the reducing power necessary for ROS detox-
ification or stimulation of gene expression for increasing
mitochondrial antioxidant defenses [26].
Another pathway in which reduced OPP may contribute
is related to secondary insults associated with abnormal
autoregulation or a breakdown in neurovascular coupling.
Here it is assumed that RGCs that function at low energy
states are susceptible to periods of ischemia or reduced
nutritional support. Such periods can happen if OPP falls
below the lower autoregulatory limit or if the functional
hyperemic reaction to visual stimulation is dysfunctional
in patients with glaucoma. These two possibilities are
discussed in the next sections.
Autoregulation
Autoregulation is the ability of a vascular bed to maintain
its BF despite changes in perfusion pressure. We have
recently provided an in-depth review on the relation
between OPP and ocular BF [27] and as such only
some of the aspects that are relevant for the present topic
will be covered. Nowadays there is evidence that retinal,
ONH and choroidal BF show some regulatory capacity in
response to changes in OPP [22,27,28]. Traditionally it
is assumed that at the lower limit of autoregulation vessels
are fully dilated. This is, however, not the case because
the hyperemic vasodilator response to flicker stimulation
is fully preserved even below the lower limit of auto-
regulation [29].
The mechanisms of autoregulation are complex and not
fully understood. In the retina and the ONH it appears
that autoregulation is strongly dependent on myogenic
and metabolic mechanisms. In the choroid the rich para-
sympathetic, sympathetic and sensory innervation as well
as intrinsic choroidal neurons plays a key role in BF
regulation in face of changes in OPP [22].
In glaucoma abnormal autoregulation of ocular BF was
observed in a large variety of studies. This includes
experiments in which IOP was modified and studies in
which the response to posture changes was assessed
[27]. Evidence for altered autoregulatory capacity in
glaucoma also arises from group correlations between
ocular BF and OPP [30–32].
The reason for abnormal autoregulation in glaucoma
patients is not fully understood (Figure 2). Obviously
reduced OPP as well as increased OPP variability may
lead to a fall of BF when the lower limit of autoregulation
is reached [27]. Increased variability of OPP and noc-
turnal BP dipping have indeed been identified as risk
factors for glaucoma [33,34,35].www.sciencedirect.com
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Abnormal autoregulation in glaucoma and factors that may contribute.
Primary vascular dysregulation, endothelial dysfunction, astrocyte
activation and increased intraocular pressure induce compromised
autoregulation leading to abnormal pressure-flow relationship. Periods
of ischemia are then more likely to occur when ocular perfusion pressure
(OPP) is reduced, when OPP fluctuates and when intraocular pressure
(IOP) is increased.Evidence has accumulated that, at least in the choroid,
BF regulates better when MAP is modified than when
IOP is modulated. This means that at the same level of
OPP BF may also depend on the absolute value of MAP
and IOP. This phenomenon has already been described
in the landmark paper by Kiel and Shepherd. The authors
have developed a rabbit model in which MAP can be
modulated by placing an occluder around the thoracic
vena cava. This allows for measurement of choroidal BF
while OPP is modified although IOP is held constant.
Interestingly BF regulated better when IOP was kept
constant at levels of 5 mmHg than at levels of 25 mmHg
[36]. In recent years we have performed several studies
indicating that this is also the case in humans [37,38,39].
As such any reduction in IOP is associated with an im-
provement in BF regulation.
Alterations in autoregulation in glaucoma may also arise
from a phenomenon called primary vascular dysregula-
tion. This term was introduced by Flammer describing
otherwise healthy subjects that show abnormal regulation
in response to temperature changes and mechanical or
emotional stress [40]. The basis for this dysregulation is
not clear, but may be related to vascular endothelial
dysfunction. Several observations indicate that endo-
thelial dysfunction is associated with glaucoma [41,42].
In addition, both endothelin and nitric oxide (NO) are
key regulators of ONH and choroidal BF at baseline and
during isometric exercise [43,44].
In the ONH there is evidence that glial cells play a role in
autoregulatory processes. This may be related to loss ofwww.sciencedirect.com autoregulation in glaucoma, because astrocytes are con-
sidered to play a key role in tissue remodeling of the
ONH [45]. It is, however, unclear how early this acti-
vation of astrocytes occurs although there is evidence that
release of substances such as glutamate and tumor necro-
sis factor a from astrocytes is involved in RGC death
[14]. In the ONH astrocytes are involved in autoregula-
tion during an increase in IOP, because the gliotoxic
agent L-2-aminoadipic acid modifies the BF response
during the decrease in OPP [46].
Neurovascular coupling
In the brain and the retina BF increases when neurons get
active, a response called functional hyperemia [47].
This phenomenon called neurovascular coupling has
attracted much interest because an abnormal BF response
to neuronal stimulation causes cell death caused by
inadequate nutrient supply. Our understanding of the
mechanisms that underlie neurovascular coupling has
increased significantly in the recent years. Astrocytes play
a key role in mediating the vasodilator response associ-
ated with neural activity. Briefly, synaptically released
glutamate activates N-methyl-D-aspartate receptors and
metabotropic glutamate receptors in neurons and astro-
cytes, respectively [47]. This leads to an increase in
intracellular Ca2+ activating arachidonic acid pathways
associated with the synthesis of vasodilators such as
prostaglandins and epoxyeicosatrienoic acids and vaso-
constrictors such as 20-hydroxy-eicosatetraenoic acid.
In addition NO synthesized from NO synthase-1 in
neurons may play a role in the vasodilator response.
Indeed, NO synthase inhibition blunts the retinal hypere-
mic response to flicker stimulation in humans [48].
Generally it is, however, believed that NO has a mod-
ulatory rather than a mediating role in the human retinal
neurovascular coupling, because the activity of the
enzymes in the arachidonic acid pathways depend on
the level of NO [49]. As such the hyperemic response
may also depend on endothelial NO related to flow-
mediated mechanisms [50].
In glaucoma the response of retinal and ONH BF to
flicker stimulation is reduced [51–53]. Factors contribut-
ing to the reduced hyperemic response in glaucoma are
presented in Figure 3. Primary vascular dysregulation
appears to be associated with abnormal retinal neurovas-
cular coupling, because vasospastic subjects show a
reduced response to flicker stimulation [54]. In keeping
with this idea endothelial dysfunction may be also related
to the altered responses seen in glaucoma [42]. The level
of IOP, however, does not appear to be directly related to
the reduced hyperemic response, because short-term
elevation does not influence flicker-induced vasodilata-
tion [29]. Activated astrocytes in glaucoma are also poten-
tial sources of impaired vasodilator response to flicker
stimulation, although this hypothesis remains unproven.Current Opinion in Pharmacology 2013, 13:36–42
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Abnormal neurovascular coupling in glaucoma and factors that may contribute. Primary vascular dysregulation, endothelial dysfunction, astrocyte
activation and neuronal dysfunction induce compromised neurovascular coupling. This will lead to periods of reduced nutrient supply (including
oxygen and glucose) during neuronal stimulation. Such periods are more likely to occur when ocular perfusion pressure (OPP) is reduced or when OPP
fluctuates.Independently of the mechanisms contributing to
reduced flicker responses in glaucoma it may well be
that abnormal neurovascular coupling plays a role in the
secondary insults to RGCs as shown in Figure 1.
Conclusions and future directions
One of the reasons why our understanding of the relation
between OPP and glaucoma is still limited lies in the
difficulties to measure retinal and ONH BF [55–58].
Doppler optical coherence tomography may become a
technique capable of measuring BF in a valid and repro-
ducible way [59–61,62]. This improvement in technol-
ogy is associated with the hope of gaining more insight
into ocular BF regulation.Figure 4
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Neuroprotective strategies need not only to consider the
neurodegenerative loss of RGCs, but also neurovascular and
neuroinflammatory components.
Current Opinion in Pharmacology 2013, 13:36–42 Is it feasible to increase OPP as part of glaucoma treat-
ment? Most probably this is not the case. On the one hand
it is pharmacologically difficult to increase OPP. On the
other hand one needs to be careful not to induce systemic
hypertension with such approaches. An exception may be
reducing anti-hypertensive treatment in patients with
systemic hypertension in order to prevent very low OPPs
[63]. When neuroprotective strategies are implemented it
appears that it is not enough to focus on the pathways that
are involved in programmed cell death of RGCs (Figure
4). Most probably neurovascular as well as neuroinflam-
matory pathways (not described in this review) need to be
targeted as well [10]. Generally the pathways leading to
primary and secondary insults in glaucoma need to be
better described to target the neurovascular component in
glaucoma.
Acknowledgements
Part of the experimental work mentioned in this article was supported by
the following grants: Fonds zur Fo¨rderung der Wissenschaftlichen
Forschung (FWF), Projects No. APP21570FW and APP21406FW, Die
O¨sterreichische Forschungsfo¨rderungsgesellschaft (FFG) project FA
607A0502, Christian Doppler Laboratory for Laser Development and their
Application in Medicine.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R,
Varotto A: Vascular risk factors for primary open angle
glaucoma: the Egna–Neumarkt Study. Ophthalmology 2000,
107:1287-1293.www.sciencedirect.com
OPP and blood flow in glaucoma Cherecheanu et al. 412. Mitchell P, Lee AJ, Rochtchina E, Wang JJ: Open-angle
glaucoma and systemic hypertension: the blue mountains eye
study. J Glaucoma 2004, 13:319-326.
3. Orzalesi N, Rossetti L, Omboni S: Vascular risk factors in
glaucoma: the results of a national survey. Graefes Arch Clin
Exp Ophthalmol 2007, 245:795-802.
4. Leske MC: Ocular perfusion pressure and glaucoma: clinical
trial and epidemiologic findings. Curr Opin Ophthalmol 2009,
20:73-78.
5. Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B: Risk
factors for incident open-angle glaucoma: the Barbados Eye
Studies. Ophthalmology 2008, 115:85-93.
6. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R:
The prevalence of glaucoma in a population-based study of
Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001,
119:1819-1826.
7. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z:
Predictors of long-term progression in the early manifest
glaucoma trial. Ophthalmology 2007, 114:1965-1972.
8. Costa VP, Arcieri ES, Harris A: Blood pressure and glaucoma. Br
J Ophthalmol 2009, 93:1276-1282.
9.

He Z, Vingrys AJ, Armitage JA, Bui BV: The role of blood pressure
in glaucoma. Clin Exp Optom 2011, 94:133-149.
A concise overview on the relation between blood pressure and glaucoma.
10.

Zlokovic BV: Neurovascular pathways to neurodegeneration in
Alzheimer’s disease and other disorders. Nat Rev Neurosci
2011, 12:723-738.
A summary of our current evidence for neurovascular involvement in
neueodegenerative disease.
11. Glucksberg MR, Dunn R: Direct measurement of retinal
microvascular pressures in the live, anesthetized cat.
Microvasc Res 1993, 45:158-165.
12. Maepea O: Pressures in the anterior ciliary arteries, choroidal
veins and choriocapillaris. Exp Eye Res 1992, 54:731-736.
13. Morgan WH, Hazelton ML, Balaratnasingamm C, Chan H,
House PH, Barry CJ, Cringle SJ, Yu DY: The association between
retinal vein ophthalmodynamometric force change and optic
disc excavation. Br J Ophthalmol 2009, 93:594-596.
14.

Osborne NN: Mitochondria: their role in ganglion cell death and
survival in primary open angle glaucoma. Exp Eye Res 2010,
90:750-757.
An in depth review of the role of mitochondrial damage in glaucomatous
ganglion cell loss.
15. Hommer A, Fuchsjager-Mayrl G, Resch H, Vass C, Garhofer G,
Schmetterer L: Estimation of ocular rigidity based on
measurement of pulse amplitude using pneumotonometry
and fundus pulse using laser interferometry in glaucoma.
Invest Ophthalmol Vis Sci 2008, 49:4046-4050.
16. Sigal IA, Ethier CR: Biomechanics of the optic nerve head. Exp
Eye Res 2009, 88:799-807.
17.

Burgoyne CF: A biomechanical paradigm for axonal insult
within the optic nerve head in aging and glaucoma. Exp Eye
Res 2011, 93:120-132.
Provides a concept of glaucoma pathogenesis with special reference to
the biomechanical properties of ocular tissues.
18. Morgan WH, Yu DY, Balaratnasingam C: The role of
cerebrospinal fluid pressure in glaucoma pathophysiology:
the dark side of the optic disc. J Glaucoma 2008, 17:408-413.
19. Berdahl JP, Allingham RR, Johnson DH: Cerebrospinal fluid
pressure is decreased in primary open-angle glaucoma.
Ophthalmology 2008, 115:763-768.
20. Ren R, Wang N, Zhang X, Cui T, Jonas JB: Trans-lamina cribrosa
pressure difference correlated with neuroretinal rim area in
glaucoma. Graefes Arch Clin Exp Ophthalmol 2011,
249:1057-1063.
21. Pache M, Flammer J: A sick eye in a sick body? Systemic
findings in patients with primary open-angle glaucoma. Surv
Ophthalmol 2006, 51:179-212.www.sciencedirect.com 22. Riva CE, Schmetterer L: Microcirculation of the ocular fundus.
In Handbook of Physiology: Microcirculation, edn 2. Edited by
Tuma RF, Dura´n WN, Ley K.Academic Press; 2008:735-765.
23.

Schmidl D, Boltz A, Kaya S, Werkmeister R, Dragostinoff N,
Lasta M, Polska E, Garhofer G, Schmetterer L: Comparison of
choroidal and optic nerve head blood flow regulation during
changes in ocular perfusion pressure. Invest Ophthalmol Vis Sci
2012, 53:4337-4346.
A study indicating that there are considerable differences in choroidal and
optic nerve head blood flow autoregulation during both an increase and a
decrease in perfusion pressure.
24. Lee S, Van Bergen NJ, Kong GY, Chrysostomou V, Waugh HS,
O’Neill EC, Crowston JG, Trounce IA: Mitochondrial dysfunction
in glaucoma and emerging bioenergetic therapies. Exp Eye Res
2011, 93:204-212.
25. Morgan JE: Retina ganglion cell degeneration in glaucoma: an
opportunity missed? A review. Clin Experiment Ophthalmol
2012, 40:364-368.
26. Perez-Pinzon MA, Stetler RA, Fiskum G: Novel mitochondrial
targets for neuroprotection. J Cereb Blood Flow Metab 2012,
32:1362-1376.
27.

Schmidl D, Garhofer G, Schmetterer L: The complex interaction
between ocular perfusion pressure and ocular blood flow –
relevance for glaucoma. Exp Eye Res 2011, 93:141-155.
A review of the current understanding of autoregulation in ocular vascular
beds.
28. Schmidl D, Boltz A, Kaya S, Werkmeister R, Dragostinoff N,
Lasta M, Polska E, Garhofer G, Schmetterer L: Comparison of
choroidal and optic nerve head blood flow regulation during
changes in ocular perfusion pressure. Invest Ophthalmol Vis Sci
2012, 53:4337-4346.
29. Garhofer G, Resch H, Weigert G, Lung S, Simader C,
Schmetterer L: Short-term increase of intraocular pressure
does not alter the response of retinal and optic nerve head
blood flow to flicker stimulation. Invest Ophthalmol Vis Sci 2005,
46:1721-1725.
30. Gherghel D, Orgul S, Gugleta K, Gekkieva M, Flammer J:
Relationship between ocular perfusion pressure and
retrobulbar blood flow in patients with glaucoma with
progressive damage. Am J Ophthalmol 2000, 130:597-605.
31. Fuchsjager-Mayrl G, Wally B, Georgopoulos M, Rainer G,
Kircher K, Buehl W, Amoako-Mensah T, Eichler HG, Vass C,
Schmetterer L: Ocular blood flow and systemic blood pressure
in patients with primary open-angle glaucoma and ocular
hypertension. Invest Ophthalmol Vis Sci 2004, 45:834-839.
32. Garhofer G, Fuchsjager-Mayrl G, Vass C, Pemp B, Hommer A,
Schmetterer L: Retrobulbar blood flow velocities in open angle
glaucoma and their association with mean arterial blood
pressure. Invest Ophthalmol Vis Sci 2010, 51:6652-6657.
33. Tokunaga T, Kashiwagi K, Tsumura T, Taguchi K, Tsukahara S:
Association between nocturnal blood pressure reduction and
progression of visual field defect in patients with primary
open-angle glaucoma or normal-tension glaucoma. Jpn J
Ophthalmol 2004, 48:380-385.
34. Choi J, Kim KH, Jeong J, Cho HS, Lee CH, Kook MS: Circadian
fluctuation of mean ocular perfusion pressure is a consistent
risk factor for normal-tension glaucoma. Invest Ophthalmol Vis
Sci 2007, 48:104-111.
35.

Sung KR, Lee S, Park SB, Choi J, Kim ST, Yun SC, Kang SY,
Cho JW, Kook MS: Twenty-four hour ocular perfusion pressure
fluctuation and risk of normal-tension glaucoma progression.
Invest Ophthalmol Vis Sci 2009, 50:5266-5274.
A study showing that ocular perfusion pressure fluctuation is an important
risk factor for glaucoma progression.
36. Kiel JW, Shepherd AP: Autoregulation of choroidal blood flow in
the rabbit. Invest Ophthalmol Vis Sci 1992, 33:2399-2410.
37.

Polska E, Simader C, Weigert G, Doelemeyer A, Kolodjaschna J,
Scharmann O, Schmetterer L: Regulation of choroidal blood
flow during combined changes in intraocular pressure and
arterial blood pressure. Invest Ophthalmol Vis Sci 2007,
48:3768-3774.Current Opinion in Pharmacology 2013, 13:36–42
42 NeurosciencesThe first human data indicating that blood flow may not only depend on
ocular perfusion pressure but also on the level of intraocular pressure and
blood pressure.
38. Fuchsjager-Mayrl G, Georgopoulos M, Hommer A, Weigert G,
Pemp B, Vass C, Garhofer G, Schmetterer L: Effect of
dorzolamide and timolol on ocular pressure: blood flow
relationship in patients with primary open-angle glaucoma
and ocular hypertension. Invest Ophthalmol Vis Sci 2010,
51:1289-1296.
39. Boltz A, Schmidl D, Weigert G, Lasta M, Pemp B, Resch H,
Garhofer G, Fuchsjager-Mayrl G, Schmetterer L: Effect of
latanoprost on choroidal blood flow regulation in healthy
subjects. Invest Ophthalmol Vis Sci 2011, 52:4410-4415.
40. Flammer J, Mozaffarieh M: Autoregulation, a balancing act
between supply and demand. Can J Ophthalmol 2008,
43:317-321.
41. Polak K, Luksch A, Berisha F, Fuchsjaeger-Mayrl G, Dallinger S,
Schmetterer L: Altered nitric oxide system in patients with
open-angle glaucoma. Arch Ophthalmol 2007, 125:494-498.
42.

Resch H, Garhofer G, Fuchsjager-Mayrl G, Hommer A,
Schmetterer L: Endothelial dysfunction in glaucoma. Acta
Ophthalmol 2009, 87:4-12.
A review summarizing our current knowledge of endothelial dysfunction in
glaucoma.
43. Luksch A, Polska E, Imhof A, Schering J, Fuchsjager-Mayrl G,
Wolzt M, Schmetterer L: Role of NO in choroidal blood flow
regulation during isometric exercise in healthy humans. Invest
Ophthalmol Vis Sci 2003, 44:734-739.
44. Fuchsjager-Mayrl G, Luksch A, Malec M, Polska E, Wolzt M,
Schmetterer L: Role of endothelin-1 in choroidal blood flow
regulation during isometric exercise in healthy humans. Invest
Ophthalmol Vis Sci 2003, 44:728-733.
45. Hernandez MR: The optic nerve head in glaucoma: role of
astrocytes in tissue remodeling. Prog Retin Eye Res 2000,
19:297-321.
46.

Shibata M, Sugiyama T, Kurimoto T, Oku H, Okuno T, Kobayashi T,
Ikeda T: Involvement of glial cells in the autoregulation of optic
nerve head blood flow in rabbits. Invest Ophthalmol Vis Sci 2012,
53:3726-3732.
The first study indicating a role for astrocyte involvement in ocular blood
flow autoregulation.
47.

Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA,
Newman EA: Glial and neuronal control of brain blood flow.
Nature 2010, 468:232-243.
This paper reviews our current understanding of cerebral neurovascular
coupling.
48. Dorner GT, Garhofer G, Kiss B, Polska E, Polak K, Riva CE,
Schmetterer L: Nitric oxide regulates retinal vascular tone in
humans. Am J Physiol Heart Circ Physiol 2003, 285:H631-H636.
49.

Kur J, Newman EA, Chan-Ling T: Cellular and physiological
mechanisms underlying blood flow regulation in the retina and
choroid in health and disease. Prog Retin Eye Res 2012,
31:377-406.
A review of ocular blood flow regulation with special emphasis on
neurovascular mechanisms.
50. Pemp B, Weigert G, Karl K, Petzl U, Wolzt M, Schmetterer L,
Garhofer G: Correlation of flicker-induced and flow-mediatedCurrent Opinion in Pharmacology 2013, 13:36–42 vasodilatation in patients with endothelial dysfunction and
healthy volunteers. Diabetes Care 2009, 32:1536-1541.
51. Garhofer G, Zawinka C, Resch H, Huemer KH, Schmetterer L,
Dorner GT: Response of retinal vessel diameters to flicker
stimulation in patients with early open angle glaucoma.
J Glaucoma 2004, 13:340-344.
52. Riva CE, Logean E, Falsini B: Visually evoked hemodynamical
response and assessment of neurovascular coupling in the
optic nerve and retina. Prog Retin Eye Res 2005, 24:183-215.
53. Gugleta K, Kochkorov A, Waldmann N, Polunina A, Katamay R,
Flammer J, Orgul S: Dynamics of retinal vessel response to
flicker light in glaucoma patients and ocular hypertensives.
Graefes Arch Clin Exp Ophthalmol 2012, 250:589-594.
54. Gugleta K, Zawinka C, Rickenbacher I, Kochkorov A, Katamay R,
Flammer J, Orgul S: Analysis of retinal vasodilation after flicker
light stimulation in relation to vasospastic propensity. Invest
Ophthalmol Vis Sci 2006, 47:4034-4041.
55. Sugiyama T, Araie M, Riva CE, Schmetterer L, Orgul S: Use of
laser speckle flowgraphy in ocular blood flow research. Acta
Ophthalmol 2010, 88:723-729.
56. Riva CE, Geiser M, Petrig BL: Ocular blood flow assessment
using continuous laser Doppler flowmetry. Acta Ophthalmol
2010, 88:622-629.
57. Garhofer G, Bek T, Boehm AG, Gherghel D, Grunwald J,
Jeppesen P, Kergoat H, Kotliar K, Lanzl I, Lovasik JV et al.: Use of
the retinal vessel analyzer in ocular blood flow research. Acta
Ophthalmol 2010, 88:717-722.
58. Stalmans I, Vandewalle E, Anderson DR, Costa VP, Frenkel RE,
Garhofer G, Grunwald J, Gugleta K, Harris A, Hudson C et al.: Use
of colour Doppler imaging in ocular blood flow research. Acta
Ophthalmol 2011, 89:e609-e630.
59. Werkmeister RM, Dragostinoff N, Pircher M, Gotzinger E,
Hitzenberger CK, Leitgeb RA, Schmetterer L: Bidirectional
Doppler Fourier-domain optical coherence tomography for
measurement of absolute flow velocities in human retinal
vessels. Opt Lett 2008, 33:2967-2969.
60. Wang Y, Lu A, Gil-Flamer J, Tan O, Izatt JA, Huang D:
Measurement of total blood flow in the normal human retina
using Doppler Fourier-domain optical coherence tomography.
Br J Ophthalmol 2009, 93:634-637.
61. Baumann B, Potsaid B, Kraus MF, Liu JJ, Huang D, Hornegger J,
Cable AE, Duker JS, Fujimoto JG: Total retinal blood flow
measurement with ultrahigh speed swept source/Fourier
domain OCT. Biomed Opt Express 2011, 2:1539-1552.
62.

Werkmeister RM, Dragostinoff N, Palkovits S, Told R, Boltz A,
Leitgeb RA, Gro¨schl M, Garho¨fer G, Schmetterer L: Measurement
of absolute blood flow velocity and blood flow in the human
retina by dual-beam bidirectional Doppler Fourier-domain
optical coherence tomography. Invest Ophthalmol Vis Sci 2012,
53:6062-6071.
A study showing that Doppler OCT is a valid method for measuring retinal
blood flow.
63. Topouzis F, Coleman AL, Harris A, Jonescu-Cuypers C, Yu F,
Mavroudis L, Anastasopoulos E, Pappas T, Koskosas A,
Wilson MR: Association of blood pressure status with the optic
disk structure in non-glaucoma subjects: the Thessaloniki eye
study. Am J Ophthalmol 2006, 142:60-67.www.sciencedirect.com
